<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24975" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Meningococcal Prophylaxis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>&#x00141;yczko</surname>
            <given-names>Katarzyna</given-names>
          </name>
          <aff>Medical University of Warsaw</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Borger</surname>
            <given-names>Judith</given-names>
          </name>
          <aff>Campbell Un. School of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Katarzyna &#x00141;yczko declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Judith Borger declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24975.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Neisseria meningitidis is a gram-negative bacterium that inhabits the mucosal surface of the nasopharynx in approximately 10% of healthy persons. The invasive meningococcal disease (IMD) is a severe form of Neisseria meningitidis infection, most commonly manifested as meningitis or septicemia. Initially, non-specific symptoms of infection with fever often lead to a rapid deterioration of the patient's condition and death within 12 to 24 hours of the onset of the disease. This activity reviews Neisseria meningitidis as a disease and discusses the role of the interprofessional team in educating patients on the need for meningococcal prophylaxis and the options available.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the global health burden of meningococcal disease.</p></list-item><list-item><p>Describe the modalities available for post-exposure chemoprophylaxis of meningococcal disease.</p></list-item><list-item><p>Review the indications for meningococcal meningitis prophylaxis.</p></list-item><list-item><p>Explain the features of Neisseria meningitidis as a disease and discuss the need for meningococcal prophylaxis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24975&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24975">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24975.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p><italic toggle="yes">Neisseria meningitidis</italic> is a gram-negative bacterium that inhabits the mucosal surface of the nasopharynx in approximately 10% of healthy persons. The invasive meningococcal disease (IMD) is a severe form of <italic toggle="yes">Neisseria meningitidis</italic> infection, most commonly manifested as meningitis or septicemia. Initially, non-specific symptoms of infection with fever often lead to a rapid deterioration of the patient's condition and death within 12 to 24 hours of the onset of the disease. The infection may occur in the form of sporadic, epidemic, or pandemic disease. The incidence of IMD is estimated at 0.3 to 3/100,000 residents in developed countries,<xref ref-type="bibr" rid="article-24975.r1">[1]</xref>&#x000a0;reaching up to 10 to 25/100,000 in some less developed&#x000a0;countries.<xref ref-type="bibr" rid="article-24975.r2">[2]</xref>&#x000a0;The prevalence of IMD peaks among persons in three age groups: infants and children aged younger than 5 years (the incidence in infants aged younger than 1 year reaches 2.6 cases per 100,000), adolescents and young adults aged 16 to 21 years (0.4 cases per 100,000), and people 65 years of age (0.3 cases per 100,000).<xref ref-type="bibr" rid="article-24975.r3">[3]</xref>&#x000a0;Approximately 5% to 20% of IMD cases occur as sepsis, with high mortality of up to 20% to 80%.<xref ref-type="bibr" rid="article-24975.r4">[4]</xref><xref ref-type="bibr" rid="article-24975.r2">[2]</xref>&#x000a0;Meningococcal meningitis results in a lower rate of morbidity of 55 to 18%.<xref ref-type="bibr" rid="article-24975.r5">[5]</xref>&#x000a0;Nonetheless, 11 to 19% of survivors experience serious sequelae (e.g., neurologic disability, limb loss, and hearing loss).<xref ref-type="bibr" rid="article-24975.r6">[6]</xref></p>
        <p>The diversity of capsular antigens on the surface of the bacteria allowed the distinction of 12 serotypes of <italic toggle="yes">N. meningitidis</italic>. Types A, B, C, Y, W are responsible for more than 90% of IMD cases globally. Serogroup B leads to approximately 60% of disease among children aged younger than&#x000a0;5 years, while serogroups C, Y, or W cause 73% of IMD cases in a group of persons aged equal to 11 years.<xref ref-type="bibr" rid="article-24975.r3">[3]</xref>&#x000a0;Types A and C are responsible for most epidemic outbreaks, while infection with type B usually occurs as a sporadic disease. <italic toggle="yes">N.&#x000a0;meningitidis</italic> is spread through droplets from the upper respiratory tract of colonized individuals (saliva and other respiratory secretions during coughing, sneezing, kissing, and chewing on toys), both by patients affected by the disease and also the asymptomatic carriers of bacteria.</p>
        <p>The great burden of the disease has led to the&#x000a0;implementation of various strategies to prevent IMD.</p>
      </sec>
      <sec id="article-24975.s3" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>
<bold>Meningococcal Vaccination</bold>
</p>
        <p>
<bold>Meningococcal Polysaccharide Vaccine</bold>
</p>
        <p>There are three types of meningococcal vaccines. The oldest vaccine is a polysaccharide containing fragments of the meningococcal polysaccharide capsule of four serotypes as antigens (MPSV4). These vaccines are characterized by low immunogenicity in children, so they should not be used for primary immunization in patients younger than 5 years. They are effective as booster doses after vaccination with a conjugate vaccine.<xref ref-type="bibr" rid="article-24975.r3">[3]</xref></p>
        <p>
<bold>Meningococcal C Conjugate Vaccines (MenCC)</bold>
</p>
        <p>The conjugated vaccines, similarly like polysaccharide one, contains fragments of the <italic toggle="yes">N. meningitidis</italic> capsule antigens, although they are linked to a protein that is most often a tetanus toxin (MenACWY-D) or a genetically modified diphtheria toxin (MenACWY-CRM). This combination makes these vaccines immunogenic even in the youngest infants. They effectively&#x000a0;generate immunological memory and reduce the nasopharyngeal carriage.<xref ref-type="bibr" rid="article-24975.r7">[7]</xref>&#x000a0;Currently available conjugated vaccines are designed as monovalent ones against serogroup C, bivalent against serogroups C and Y, or quadrivalent vaccine against types C, A, W, and Y.</p>
        <p>The recommendations on MenCC vaccine use vary in different regions. The first country to implement a routine MenCC vaccination into their national childhood immunization program was the United Kingdom in 1999, then followed by other European countries. The routine campaign in the United Kingdom&#x000a0;was directed to infants (first dose at 2 months of age), but catch-up programs for other age groups led rapidly to high coverage in all persons in a group aged 2 months to 22 years. Public MenCC vaccination contributed to a reduction in serogroup C nasopharyngeal carriage and reduction of <italic toggle="yes">N. meningitidis</italic> type C IMD in unvaccinated age groups (herd protection).<xref ref-type="bibr" rid="article-24975.r7">[7]</xref><xref ref-type="bibr" rid="article-24975.r8">[8]</xref>&#x000a0;In the&#x000a0;United States, the vaccine was licensed in 2005 and is routinely recommended for adolescents and those at high risk of developing IMD.<xref ref-type="bibr" rid="article-24975.r3">[3]</xref></p>
        <p>Numerous studies have confirmed the efficacy of the meningococcal C conjugate vaccines. In a large epidemiological study conducted in Europe from 2004 through 2014, a significant decrease in IMD prevalence was observed in countries with established MenCC vaccination programs. In countries that had introduced routine MenCC vaccines into their national vaccination program before 2004 and between 2004 and 2014, an annual decrease of 10.2% and 8.3%, respectively, was observed. No significant trend was observed in countries with no routine MenCC vaccination.<xref ref-type="bibr" rid="article-24975.r9">[9]</xref>&#x000a0;According to the European Center for Disease Prevention and Control (ECDC) surveillance of invasive bacterial disease in Europe 2008/2009, the incidence of serogroup C IMD is substantially lower in countries with MenCC vaccine included in their vaccination schedule than in countries with no established MenCC vaccination program: 0.54 vs. 1.01/100&#x000a0;000 among infants, 0.22 vs. 0.45/100&#x000a0;000 in toddlers, 0.17 vs. 0.29/100&#x000a0;000 in adolescents.</p>
        <p>
<bold>Centers for Disease Control (CDC) Recommendations on Meningococcal C Conjugate Vaccine<xref ref-type="bibr" rid="article-24975.r3">[3]</xref></bold>
</p>
        <p>According to the CDC, all children aged 11 to 12 should be vaccinated with one dose of a conjugate meningococcal vaccine. Since protection wanes, whose vaccinated before 16 years of age require a booster dose administered with an interval of a minimum of 8 weeks, preferably at the age of&#x000a0;16 to 18 years. If the first dose was introduced in a person older than 16 years, the booster dose is not recommended.</p>
        <p>Although routine vaccination of infants and young children is not recommended, all patients aged 2 months to 10 years should receive the conjugate vaccine if they belong to a high-risk group of developing IMD.</p>
        <p>Adults should receive a conjugate meningococcal vaccine if they meet risk factors. For healthy individuals, one-dose&#x000a0;vaccination is scheduled. For patients suffering from congenital or acquired immune deficiency (e.g., anatomical or functional asplenia, HIV infection, persistent complement component deficiency, eculizumab use), two doses of primary vaccination implemented with an&#x000a0;8-week interval are recommended. If the risk remains, both groups should receive the booster dose of the same preparation every 5 years.<xref ref-type="bibr" rid="article-24975.r3">[3]</xref></p>
        <p>Meningococcal conjugate vaccines may be given to pregnant women who&#x000a0;are at increased risk for meningococcal disease.<xref ref-type="bibr" rid="article-24975.r3">[3]</xref></p>
        <p>
<bold>Meningococcal B Protein Vaccine (MenB)</bold>
</p>
        <p>The third meningococcal vaccine group includes protein vaccines designed against group B meningococci. They are characterized by good immunogenicity; however, no data is available concerning how long their effectiveness persists due to the relatively short time of their use. In Europe,&#x000a0;it was licensed in 2013. Since 2015, MenB vaccination had been included in the United Kingdom national childhood vaccination schedule; subsequently, other countries, including Ireland and Italy, followed. It is not publicly funded but strongly recommended in most of the other European countries. The quadrivalent MenB vaccine has been proved to produce a good immune response in children older than 2 months.<xref ref-type="bibr" rid="article-24975.r10">[10]</xref>&#x000a0;In 2017, the ECDC expert group considered infants under 1 year of age as the primary target group for MenB vaccination. In the United States, MenB vaccination&#x000a0;is recommended for adolescents and adults at a high risk of serogroup B IMD (see CDC recommendations below).<xref ref-type="bibr" rid="article-24975.r3">[3]</xref></p>
        <p>
<bold>CDC Recommendations on Meningococcal B vaccine<xref ref-type="bibr" rid="article-24975.r3">[3]</xref></bold>
</p>
        <p>MenB vaccines are recommended for adolescents aged 10 and older belonging to the risk factors group. The preferred age for MenB vaccination is 16 to 18 years.<xref ref-type="bibr" rid="article-24975.r11">[11]</xref>&#x000a0;The full primary vaccination consists&#x000a0;of two or three doses, depending on the preparation. The preparations are interchangeable, and the same product must be&#x000a0;used for all doses.</p>
        <p>As there are no randomized controlled trials concerning the safety of MenB vaccines, use in pregnant or lactation women, the vaccination may be implemented only in case of increased risk of developing B-type meningococcal disease when the potential benefits outweigh the risks.<xref ref-type="bibr" rid="article-24975.r11">[11]</xref></p>
      </sec>
      <sec id="article-24975.s4" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Chemoprophylaxis of Invasive Meningococcal Disease</bold>
</p>
        <p>As the meningococcal infection spreads with droplets, the disease is a serious threat for both the patient and close contacts. The risk of developing the disease for household contacts exposed to patients who have sporadic meningococcal disease was estimated to be 4:1000 exposed people, which is 500 to 800 times greater than the risk for the total population.<xref ref-type="bibr" rid="article-24975.r6">[6]</xref>&#x000a0;The risk for health care providers exposed to infected patients is 25 times higher than for a general population.<xref ref-type="bibr" rid="article-24975.r12">[12]</xref>&#x000a0;Chemoprophylaxis aims to prevent the illness among close contacts.</p>
        <p>
<bold>Indications</bold>
</p>
        <p>Following CDC recommendations, the strategy of meningococcal prophylaxis should be implemented within 24 hours after contact or identification of the pathogen. In cases of a delayed report of IMD, the realization of chemoprophylaxis is reasoned up to 14 days from the disease onset.<xref ref-type="bibr" rid="article-24975.r6">[6]</xref>&#x000a0;The decision about chemoprophylaxis implementation should not be based on nasopharyngeal culture.</p>
        <p>The indications for chemoprophylaxis implementation are as follows.<xref ref-type="bibr" rid="article-24975.r6">[6]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Close contact with a patient within 7 days before the disease onset, regardless of vaccination status. "Close contact" applies to:
<list list-type="bullet"><list-item><p>Household members living with a sick person</p></list-item><list-item><p>People who&#x000a0;are in intimate contact with the patient</p></list-item><list-item><p>People sleeping in the same bedroom with the patient (students, soldiers, officers)</p></list-item><list-item><p>People who have been in direct contact with secretions from the patient's respiratory tract during medical procedures, including mouth-to-mouth resuscitation, suctioning, and endotracheal intubation, before or less than 24 hours after&#x000a0;antimicrobial therapy was initiated</p></list-item><list-item><p>People traveling with the patient in the same plane, ship, bus, or car for longer than 8 hours</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>The patient himself before discharge from a&#x000a0;hospital if they were not treated with ceftriaxone.</p>
          </list-item>
        </list>
        <p>Drinking from the same bottle, using the same cutlery, or smoking the same cigarette, is not an indication of the implementation of prophylaxis unless there is an additional risk of close contact described above.</p>
        <p>
<bold>Antibiotics</bold>
</p>
        <p>Antibiotics effective in eliminating the carriage of <italic toggle="yes">N. meningitidis</italic>, therefore recommended in chemoprophylaxis of IMD are rifampicin, ciprofloxacin, and ceftriaxone.<xref ref-type="bibr" rid="article-24975.r13">[13]</xref></p>
        <p>Rifampicin</p>
        <p>Rifampicin can be used in every age group. Contraindications to its use include pregnancy, jaundice, and hypersensitivity to the drug. Rifampicin is the most powerful known inducer&#x000a0;of the hepatic cytochrome P450enzyme system, therefore increases the metabolism of many drugs. Patients undergoing long-term anticoagulation therapy with warfarin&#x000a0;have to increase their dosage and have their clotting time frequently checked because failure to do so could lead to inadequate anticoagulation, resulting in serious consequences of thromboembolism. Rifampicin can reduce the efficacy of birth control pills&#x000a0;or other hormonal contraception. Patients receiving rifampicin should be informed of the possibility of side effects such as urine, stool, sweat, or tears discolor in red or orange.<xref ref-type="bibr" rid="article-24975.r13">[13]</xref></p>
        <p>Ciprofloxacin</p>
        <p>Ciprofloxacin is intended for use only in adults (older than 18 years of age). It is contraindicated in children, pregnant women, and nursing mothers.<xref ref-type="bibr" rid="article-24975.r13">[13]</xref>&#x000a0;</p>
        <p>Ceftriaxone</p>
        <p>Ceftriaxone may be used in every age group, although the intramuscular route of administration makes it less convenient. Ceftriaxone is a first-line antibiotic recommended as chemoprophylaxis of IMD in pregnancy and nursing mothers.<xref ref-type="bibr" rid="article-24975.r13">[13]</xref></p>
        <p>Azithromycin</p>
        <p>The effectiveness of azithromycin in eliminating the nasopharyngeal carriage of <italic toggle="yes">N. meningitidis</italic> has been proven in only one study in adults.<xref ref-type="bibr" rid="article-24975.r14">[14]</xref>&#x000a0;According to AAP, azithromycin can be used for chemoprophylaxis, where ciprofloxacin resistance has been detected.</p>
        <p>Some regions have documented resistance of <italic toggle="yes">N. meningitidis</italic> to ciprofloxacin or rifampicin.<xref ref-type="bibr" rid="article-24975.r13">[13]</xref>&#x000a0;Local societies should update their recommendations of antibiotics used in IMD chemoprophylaxis based on regional resistance data. Although the presented chemoprophylaxis effectiveness reaches up to 90% to 95%, it does not provide 100% protection against the disease. Patients who have received antibiotic therapy should be informed about the symptoms of the meningococcal disease and the need to report to the hospital instantly in case they occur.</p>
        <p>
<bold>Post-Exposure Immunoprophylaxis</bold>
</p>
        <p>A secondary case can occur several weeks after the index one; therefore,&#x000a0;a meningococcal vaccine is a supporting strategy in meningococcal prophylaxis. In outbreaks caused by serogroups A, C, Y, and W, local authorities should decide on mass vaccination campaigns.</p>
      </sec>
      <sec id="article-24975.s5" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>All primary caregivers must be familiar with vaccination guidelines. An interprofessional approach is best to improve vaccination rates and post-exposure prophylaxis. This team includes physicians, nurses, and pharmacists. If there is any doubt about vaccination against <italic toggle="yes">N. meningitides</italic>, an infectious disease consultation&#x000a0;is highly recommended.&#x000a0;</p>
      </sec>
      <sec id="article-24975.s6">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24975&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24975">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24975/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24975">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-24975.s7">
        <fig id="article-24975.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Meningococcal prophylaxis Tables Contributed by Katarzyna Wzorek-&#x00141;yczko</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Meningococcal__prophylaxis__tables__" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-24975.s8">
        <title>References</title>
        <ref id="article-24975.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halperin</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Bettinger</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Greenwood</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Jelfs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ladhani</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ramsay</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>S&#x000e1;fadi</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>The changing and dynamic epidemiology of meningococcal disease.</article-title>
            <source>Vaccine</source>
            <year>2012</year>
            <month>May</month>
            <day>30</day>
            <volume>30 Suppl 2</volume>
            <fpage>B26</fpage>
            <page-range>B26-36</page-range>
            <pub-id pub-id-type="pmid">22178525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24975.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Deuren</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brandtzaeg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van der Meer</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Update on meningococcal disease with emphasis on pathogenesis and clinical management.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>144</fpage>
            <page-range>144-66, table of contents</page-range>
            <pub-id pub-id-type="pmid">10627495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24975.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohn</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>MacNeil</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Ortega-Sanchez</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Briere</surname>
                <given-names>EZ</given-names>
              </name>
              <name>
                <surname>Meissner</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Messonnier</surname>
                <given-names>NE</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention (CDC)</collab>
            </person-group>
            <article-title>Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2013</year>
            <month>Mar</month>
            <day>22</day>
            <volume>62</volume>
            <issue>RR-2</issue>
            <fpage>1</fpage>
            <page-range>1-28</page-range>
            <pub-id pub-id-type="pmid">23515099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24975.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brigham</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Sandora</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Neisseria meningitidis: epidemiology, treatment and prevention in adolescents.</article-title>
            <source>Curr Opin Pediatr</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>437</fpage>
            <page-range>437-43</page-range>
            <pub-id pub-id-type="pmid">19421058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24975.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pace</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pollard</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Meningococcal disease: clinical presentation and sequelae.</article-title>
            <source>Vaccine</source>
            <year>2012</year>
            <month>May</month>
            <day>30</day>
            <volume>30 Suppl 2</volume>
            <fpage>B3</fpage>
            <page-range>B3-9</page-range>
            <pub-id pub-id-type="pmid">22607896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24975.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bilukha</surname>
                <given-names>OO</given-names>
              </name>
              <name>
                <surname>Rosenstein</surname>
                <given-names>N</given-names>
              </name>
              <collab>National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC)</collab>
            </person-group>
            <article-title>Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2005</year>
            <month>May</month>
            <day>27</day>
            <volume>54</volume>
            <issue>RR-7</issue>
            <fpage>1</fpage>
            <page-range>1-21</page-range>
            <pub-id pub-id-type="pmid">15917737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24975.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramsay</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Trotter</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Kaczmarski</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.</article-title>
            <source>BMJ</source>
            <year>2003</year>
            <month>Feb</month>
            <day>15</day>
            <volume>326</volume>
            <issue>7385</issue>
            <fpage>365</fpage>
            <page-range>365-6</page-range>
            <pub-id pub-id-type="pmid">12586669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24975.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trotter</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Kaczmarski</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ramsay</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.</article-title>
            <source>Lancet</source>
            <year>2004</year>
            <month>Jul</month>
            <day>24-30</day>
            <volume>364</volume>
            <issue>9431</issue>
            <fpage>365</fpage>
            <page-range>365-7</page-range>
            <pub-id pub-id-type="pmid">15276396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24975.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whittaker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dias</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Ramliden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>K&#x000f6;dm&#x000f6;n</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Economopoulou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pastore Celentano</surname>
                <given-names>L</given-names>
              </name>
              <collab>ECDC network members for invasive meningococcal disease</collab>
            </person-group>
            <article-title>The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014.</article-title>
            <source>Vaccine</source>
            <year>2017</year>
            <month>Apr</month>
            <day>11</day>
            <volume>35</volume>
            <issue>16</issue>
            <fpage>2034</fpage>
            <page-range>2034-2041</page-range>
            <pub-id pub-id-type="pmid">28314560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24975.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parikh</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Beebeejaun</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Borrow</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramsay</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Ladhani</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <month>Dec</month>
            <day>03</day>
            <volume>388</volume>
            <issue>10061</issue>
            <fpage>2775</fpage>
            <page-range>2775-2782</page-range>
            <pub-id pub-id-type="pmid">28100432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24975.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Folaranmi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>MacNeil</surname>
                <given-names>JR</given-names>
              </name>
              <collab>Centers for Disease Control (CDC)</collab>
            </person-group>
            <article-title>Use of Serogroup B Meningococcal Vaccines in Persons Aged &#x02265;10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2015</year>
            <month>Jun</month>
            <day>12</day>
            <volume>64</volume>
            <issue>22</issue>
            <fpage>608</fpage>
            <page-range>608-12</page-range>
            <pub-id pub-id-type="pmid">26068564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24975.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilmore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stuart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Risk of secondary meningococcal disease in health-care workers.</article-title>
            <source>Lancet</source>
            <year>2000</year>
            <month>Nov</month>
            <day>11</day>
            <volume>356</volume>
            <issue>9242</issue>
            <fpage>1654</fpage>
            <page-range>1654-5</page-range>
            <pub-id pub-id-type="pmid">11089828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24975.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zalmanovici Trestioreanu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gafter-Gvili</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leibovici</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Antibiotics for preventing meningococcal infections.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2011</year>
            <month>Aug</month>
            <day>10</day>
            <issue>8</issue>
            <fpage>CD004785</fpage>
            <pub-id pub-id-type="pmid">21833949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24975.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Girgis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Frenck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>El-Gendy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Farid</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mateczun</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>816</fpage>
            <page-range>816-9</page-range>
            <pub-id pub-id-type="pmid">9779768</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
